@laurentdercle brilliantly showing how it’s getting harder to ignore the benefits of AI in medical oncology. Interesting comparison between using AI vs RECIST when predicting OS #ESMO25#AI#Immunotherapy#biomarkers
Fantastic talk by @MLAscierto re: transcriptomics. Immunotherapy so widely used, and previously so little known about why resistance develops. Excited to watch this space #ESMO25
Young Oncologists Group of Australia (YOGA) is running a Transitioning to Consultant Workshop on Sat 30 November!
Location: Online
11am - 1pm AEDT
More Info/Register:
https://t.co/epPuGUBuA4
@ausyoungoncs
Long term follow up from COMBI-AD presented by @ProfGLongMIA. Sustained improvement in RFS and DMFS with adjuvant dab/tram vs placebo at 8 years. . #ASCO24@OncoAlert
Amazing talk from @drlouiseemmett highlighting the positive results of ENZA-p, paving the way for many other active trials studying drug + radionuclide combinations @ANZUPtrials#ESMO23
Fantastic talk by @SantiagoZelenay: adding COX-2i to IO is a cheap, readily available, and effective way to modulate the TME & overcome resistance #ESMO23
#MOGA23 started with a downpour, but fittingly finished like this, a (near) perfect blue sky over the Derbarl Yerrigan. Thank you @drtclay & @oncologyknitwit for convening, and to everyone at @MOGA_ORG & @ausyoungoncs for organising an incredible few days 👏🏻
Liesel Byrne giving an update of ADDIKD guidelines at #MOGA23, concerning renal function in anticancer treatment dosing. Yet another important & easily accessible resource from #eviQ 👏🏻 @MOGA_ORG@cancerNSW
#MOGA23
Prof Thompson
Lack of understanding around Aboriginal patient needs
- need for family support
- fear of treatment and dying
- logistical issues to get to and access care
Prof Sandra Thompson providing some really important insights & perspectives into cancer in Australia’s indigenous populations, highlighting a increasing difference in outcomes #MOGA23#closingthegap